Literature DB >> 14699054

Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia.

Jay Y Cho1, Changsheng Guo, Monica Torello, Gregory P Lunstrum, Tomoko Iwata, Chuxia Deng, William A Horton.   

Abstract

Mutations of fibroblast growth factor receptor 3 (FGFR3) are responsible for achondroplasia (ACH) and related dwarfing conditions in humans. The pathogenesis involves constitutive activation of FGFR3, which inhibits proliferation and differentiation of growth plate chondrocytes. Here we report that activating mutations in FGFR3 increase the stability of the receptor. Our results suggest that the mutations disrupt c-Cbl-mediated ubiquitination that serves as a targeting signal for lysosomal degradation and termination of receptor signaling. The defect allows diversion of actively signaling receptors from lysosomes to a recycling pathway where their survival is prolonged, and, as a result, their signaling capacity is increased. The lysosomal targeting defect is additive to other mechanisms proposed to explain the pathogenesis of ACH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14699054      PMCID: PMC327195          DOI: 10.1073/pnas.2237184100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

Review 1.  Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases.

Authors:  H Waterman; Y Yarden
Journal:  FEBS Lett       Date:  2001-02-16       Impact factor: 4.124

Review 2.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

3.  The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.

Authors:  E Monsonego-Ornan; R Adar; T Feferman; O Segev; A Yayon
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.

Authors:  Y Wang; M K Spatz; K Kannan; H Hayk; A Avivi; M Gorivodsky; M Pines; A Yayon; P Lonai; D Givol
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

5.  Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice.

Authors:  S Garofalo; M Kliger-Spatz; J L Cooke; O Wolstin; G P Lunstrum; S M Moshkovitz; W A Horton; A Yayon
Journal:  J Bone Miner Res       Date:  1999-11       Impact factor: 6.741

6.  Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis.

Authors:  L Chen; R Adar; X Yang; E O Monsonego; C Li; P V Hauschka; A Yayon; C X Deng
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

7.  Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.

Authors:  K C Hart; S C Robertson; D J Donoghue
Journal:  Mol Biol Cell       Date:  2001-04       Impact factor: 4.138

8.  Uptake and intracellular transport of acidic fibroblast growth factor: evidence for free and cytoskeleton-anchored fibroblast growth factor receptors.

Authors:  L Citores; J Wesche; E Kolpakova; S Olsnes
Journal:  Mol Biol Cell       Date:  1999-11       Impact factor: 4.138

9.  Differential effects of fibroblast growth factor (FGF) 9 and FGF2 on proliferation, differentiation and terminal differentiation of chondrocytic cells in vitro.

Authors:  N B Weksler; G P Lunstrum; E S Reid; W A Horton
Journal:  Biochem J       Date:  1999-09-15       Impact factor: 3.857

10.  Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization.

Authors:  J Schlessinger; A N Plotnikov; O A Ibrahimi; A V Eliseenkova; B K Yeh; A Yayon; R J Linhardt; M Mohammadi
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

View more
  38 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

2.  Hand and foot abnormalities associated with genetic diseases.

Authors:  Henry J Mankin; Jesse Jupiter; Carol Ann Trahan
Journal:  Hand (N Y)       Date:  2010-10-26

Review 3.  Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics.

Authors:  Edwin Li; Kalina Hristova
Journal:  Cell Adh Migr       Date:  2010-04-23       Impact factor: 3.405

Review 4.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.

Authors:  Edwin Li; Kalina Hristova
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

Review 5.  Degradation of activated protein kinases by ubiquitination.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

6.  Forster resonance energy transfer measurements of transmembrane helix dimerization energetics.

Authors:  Mikhail Merzlyakov; Kalina Hristova
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

7.  Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.

Authors:  Changsheng Guo; Catherine R Degnin; Melanie B Laederich; Gregory P Lunstrum; Paul Holden; Jeanie Bihlmaier; Deborah Krakow; Yoon-Jae Cho; William A Horton
Journal:  Cell Signal       Date:  2008-04-10       Impact factor: 4.315

8.  Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies.

Authors:  Eduard V Bocharov; Dmitry M Lesovoy; Sergey A Goncharuk; Marina V Goncharuk; Kalina Hristova; Alexander S Arseniev
Journal:  Structure       Date:  2013-10-10       Impact factor: 5.006

9.  DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma.

Authors:  Guiji Zhang; Xia Tang; Li Liang; Wanfeng Zhang; Dewei Li; Xiaoyuan Li; Dachun Zhao; Yaqiu Zheng; Yanhong Chen; Bingtao Hao; Kai Wang; Ni Tang; Keyue Ding
Journal:  Oncogene       Date:  2020-02-19       Impact factor: 9.867

10.  Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.

Authors:  Jianghua Wang; Wendong Yu; Yi Cai; Chengxi Ren; Michael M Ittmann
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.